/
Oncology
Advanced Solid Tumors
287
Pipeline Programs↗
254
Active Trials↗
233
Companies Involved↗
Advanced Solid Tumors is a highly competitive landscape with 287 programs across 233 companies. The most active players are AbbVie, Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 1139
Phase 2124
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
217 of 265 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 265 classified programs, each share of the total. Modality classified for 100% of 287 pipeline programs.
Analysis
Trial Status
821
clinical trials
Completed326 · 40%
Recruiting164 · 20%
Terminated139 · 17%
Unknown status84 · 10%
Not yet recruiting46 · 6%
Active, not recruiting43 · 5%
Other19 · 2%
Clinical Trials
Trial Activity
821 trials
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT06730659·36 enrolled
Page 1 of 55
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)